3-benzyloxy-5-ethoxy-benxaldehyde | 227023-81-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-benzyloxy-5-ethoxy-benxaldehyde
• 英文别名: 3-benzyloxy-5-ethoxy-benzaldehyde；3-Ethoxy-5-phenylmethoxybenzaldehyde
• CAS: 227023-81-6
• 化学式: C₁₆H₁₆O₃
• 分子量: 256.301
• InChiKey: NLEWRCUAXUANLJ-UHFFFAOYSA-N

物化性质

• 沸点：
  416.0±30.0 °C(Predicted)
• 密度：
  1.132±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-benzyloxy-5-ethoxy-benxaldehyde 在 N-甲基吡咯烷酮 、 palladium on activated charcoal 盐酸 、 甲醇 、 tris(dibenzylideneacetone)dipalladium (0) 、 三苯胂 、 TEA 、 水 、 氢气 、 lithium chloride 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 氯仿 为溶剂， 生成 (4-Carbamimidoyl-phenylamino)-(3-ethoxy-5-pyridin-3-yl-phenyl)-acetic acid methyl ester
  参考文献：
  名称：

  Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors

  摘要：

  We describe the structure-based design and synthesis of highly potent, orally bioavailable tissue factor/factor Vila inhibitors which interfere with the coagulation cascade by selective inhibition of the extrinsic pathway. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.079
• 作为产物：
  描述：

  3,5-二羟基苯甲醇 在 manganese(IV) oxide 、 potassium carbonate 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-benzyloxy-5-ethoxy-benxaldehyde
  参考文献：
  名称：

  Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors

  摘要：

  We describe the structure-based design and synthesis of highly potent, orally bioavailable tissue factor/factor Vila inhibitors which interfere with the coagulation cascade by selective inhibition of the extrinsic pathway. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.079

文献信息

• Pyrimidine, quinazoline, pteridine and triazine derivatives
  申请人：Binggeli Alfred

  公开号：US20070225271A1

  公开（公告）日：2007-09-27

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A，R1至R5和G如描述和声明中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• Pyrimidine and quinazoline derivatives
  申请人：Christ Andreas D.

  公开号：US20080045550A1

  公开（公告）日：2008-02-21

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及以下式子的化合物，其中A，R1到R5和G的定义如描述和权利要求中所述，并且其药学上可接受的盐。本发明还涉及含有这些化合物的制药组合物，以及其制备过程和用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• Pyrimidine and Quinazoline Derivatives
  申请人：Christ Andreas D.

  公开号：US20100069413A1

  公开（公告）日：2010-03-18

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及公式中的化合物，其中A、R1至R5和G如描述和权利要求中所定义，并且其药学上可接受的盐。本发明还涉及含有这些化合物的药物组合物，以及制备它们的过程和它们用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity
  作者：Katrin Groebke Zbinden、David W. Banner、Kurt Hilpert、Jacques Himber、Thierry Lavé、Markus A. Riederer、Martin Stahl、Thomas B. Tschopp、Ulrike Obst-Sander

  DOI：10.1016/j.bmc.2006.03.042

  日期：2006.8

  The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial thrombosis without prolonging bleeding time. The pharmacodynamic properties of this selective inhibitor are compared to the behaviour of a mixed factor VIIa/factor Xa inhibitor. (c) 2006 Elsevier Ltd. All rights reserved.
• N-(4-carbamimido-phenyl)-glycinamidderivate
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0921116B1

  公开（公告）日：2003-06-18